Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children presenting at one of the health centres in the study area~* Symptoms suggestive of malaria~* At least 20 P.falciparum parasites per 200 leucocytes~* Living in the study area (to enable follow-up)~Exclusion Criteria:~* Danger signs~* By the responsible doctor evaluated to need to be transferred to the national hospital as an in-patient~* Previous idiosyncratic reactions to any of the study drugs

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 Coartem (Type: EXPERIMENTAL): Treatment of documented malaria in children following the dosages recommended by the manufacturer.
- 2 Chloroquine (Type: ACTIVE_COMPARATOR): The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).